

Karina Dahl Steffensen
Clinical Associate Professor
Department of Oncology
Center Lillebaelt
Email: karina.dahl.steffensen@rsyd.dk,
Phone: +45 21770727



Employment

Clinical Professor

IRS, Lillebaelt Hospital, Oncology
University of Southern Denmark
1. Sep 2014 → 31. Mar 2023

Clinical Professor

IRS, Lillebaelt Hospital, Center for Shared Decision Making
University of Southern Denmark
1. Feb 2018 → 31. Mar 2023

Director - Center for Shared Decision Making

1. Nov 2014 → present

Senior Consultant (physician) Clinical Oncology

Vejle Sygehus
Vejle, Denmark
1. Oct 2014 → present

Publications - peer reviewed papers

Practitioners' views on shared decision-making implementation: A qualitative study

Ankolekar, A., Steffensen, K. D., Olling, K., Dekker, A., Wee, L., Roumen, C., Hasannejadasl, H. & Fijten, R., 11. Nov 2021, In: PLOS ONE. 16, 11, 18 p., e0259844.

Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement

Faaborg, L., Fredslund Andersen, R., Waldstrøm, M., Høgdall, E., Høgdall, C., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., Nov 2021, In: Clinica Chimica Acta. 522, p. 152-157

HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy

Faaborg, L., Jakobsen, A., Waldstrøm, M., Petersen, C. B., Andersen, R. F. & Steffensen, K. D., Oct 2021, In: Biomarkers in Medicine. 15, 15, p. 1309-1317

Providing Balanced Information about Options in Patient Decision Aids: An Update from the International Patient Decision Aid Standards

Martin, R. W., Brogård Andersen, S., O'Brien, M. A., Bravo, P., Hoffmann, T., Olling, K., Shepherd, H. L., Dankl, K., Stacey, D. & Dahl Steffensen, K., Oct 2021, In: Medical Decision Making. 41, 7, p. 780-800

Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration

Witteman, H. O., Maki, K. G., Vaissou, G., Finderup, J., Lewis, K. B., Dahl Steffensen, K., Beaudoin, C., Comeau, S. & Volk, R. J., Oct 2021, In: Medical Decision Making. 41, 7, p. 736-754

What Works in Implementing Patient Decision Aids in Routine Clinical Settings? A Rapid Realist Review and Update from the International Patient Decision Aid Standards Collaboration

Joseph-Williams, N., Abhyankar, P., Boland, L., Bravo, P., Brenner, A. T., Brodney, S., Coulter, A., Giguere, A., Hoffman, A., Körner, M., Langford, A., Légaré, F., Matlock, D., Mounjid, N., Munro, S., Dahl Steffensen, K., Stirling, C. & van der

Weijden, T., Oct 2021, In: Medical Decision Making. 41, 7, p. 907-937

Association of patient-reported outcomes and ovarian cancer recurrence

Kargo, A. S., Jensen, P. T., Lindemann, K., Hjøllund, N. H., Liposits, G. I., Raaschou-Jensen, N., Knudsen, B. M., Möller, S., Hansen, D. G. & Steffensen, K. D., Sep 2021, In: International Journal of Gynecological Cancer. 31, 9, p. 1248-1259

ePRO-based individual follow-up care for women treated for early breast cancer: impact on service use and workflows

Riis, C. L., Stie, M., Bechmann, T., Jensen, P. T., Coulter, A., Möller, S. & Steffensen, K. D., Aug 2021, In: Journal of Cancer Survivorship. 15, 4, p. 485-496

Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial

Aghajanian, C., Bookman, M. A., Fleming, G. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Jackson, C. G., Sullivan, D., Ratajczak, C. K. & Coleman, R. L., Aug 2021, In: Gynecologic Oncology. 162, 2, p. 375-381

The impact of shared decision making on time consumption and clinical decisions. A prospective cohort study

Søndergaard, S. R., Madsen, P. H., Hilberg, O., Bechmann, T., Jakobsen, E., Jensen, K. M., Olling, K. & Steffensen, K. D., Jul 2021, In: Patient Education and Counseling. 104, 7, p. 1560-1567

Treosulfan in platinum-resistant ovarian cancer

Olesen, K. D., Larsen, A. T. R., Jensen, L. H., Steffensen, K. D. & Søndergaard, S. R., Jul 2021, In: International Journal of Gynecological Cancer. 31, 7, p. 1045-1051

Early ctDNA response to chemotherapy: A potential surrogate marker for overall survival

Jakobsen, A., Andersen, R. F., Hansen, T. F., Jensen, L. H., Faaborg, L., Steffensen, K. D., Thomsen, C. B. & Wen, S. W. C., May 2021, In: European Journal of Cancer. 149, p. 128-133

Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)

Gultekin, M., Ak, S., Ayhan, A., Strojna, A., Pletnev, A., Fagotti, A., Perrone, A. M., Erzeneoglu, B. E., Temiz, B. E., Lemley, B., Soyak, B., Hughes, C., Cibula, D., Haidopoulos, D., Brennan, D., Cola, E., van der Steen-Banasik, E., Urkmez, E., Akilli, H., Zapardiel, I. & 16 others, Tóth, I., Sehoul, J., Zalewski, K., Bahremand, K., Chiva, L., Mirza, M. R., Papageorgiou, M., Zoltan, N., Adámková, P., Morice, P., Garrido-Mallach, S., Akgor, U., Theodoulidis, V., Arik, Z., Steffensen, K. D. & Fotopoulou, C., Jan 2021, In: Cancer Medicine. 10, 1, p. 208-219

The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness

Kargo, A. S., Jensen, P. T., Lindemann, K., Hjøllund, N. H. I., Lund, B., Hæe, M., Möller, S., Hansen, D. G. & Dahl Steffensen, K., 2021, In: Acta Oncologica. 60, 4, p. 434-443

When life gives you no choice: Context of decision-making when offered an oncology clinical trial

Gregersen, T. A., Birkelund, R., Wolderslund, M., Steffensen, K. D. & Ammentorp, J., 2021, (E-pub ahead of print) In: Scandinavian Journal of Caring Sciences.

Shared decision making in high-grade glioma patients-a systematic review

von Essen, H. S., Pii, K., Steffensen, K. D. & Poulsen, F. R., 1. Dec 2020, In: Neuro-Oncology Practice. 7, 6, p. 589-598

Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients

Hansen, M. K. G., Smerdel, M. P., Waldstrøm, M., Andersen, R. F., Adimi, P., Jakobsen, A. & Steffensen, K. D., Dec 2020, In: Cancer Chemotherapy and Pharmacology. 86, p. 751-759

Geographical distance as an impeding factor for cancer patients' participation in a specialised exercise programme

Hansen, A. M. E., Hansen, T. F., Steffensen, K. D. & Jensen, L. H., 30. Nov 2020, In: Danish Medical Journal. 67, 12, 8 p., A01200044.

Blood natural killer cells during treatment in recurrent ovarian cancer

Henriksen, J. R., Nederby, L., Donskov, F., Waldstrøm, M., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., Nov 2020, In: Acta Oncologica. 59, 11, p. 1365-1373

Cabazitaxel - A treatment option in recurrent platinum-resistant ovarian cancer

Vestergaard Madsen, C., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., Sep 2020, In: Anticancer Research. 40, 9, p. 5255-5261

Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol

Kargo, A. S., Coulter, A., Lindemann, K., Jensen, P. T., Hjøllund, N. H., Mosgaard, B. J. & Steffensen, K. D., Sep 2020, In: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 30, 9, p. 1444-1449

Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma

Henriksen, J. R., Donskov, F., Waldstrøm, M., Jakobsen, A., Hjortkjaer, M., Petersen, C. B. & Dahl Steffensen, K., Jun 2020, In: Acta Oncologica. 59, 6, p. 652-659

Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy

Henriksen, J. R., Nederby, L., Donskov, F., Waldstrøm, M., Adimi, P., Jakobsen, A. & Steffensen, K. D., 15. May 2020, In: Journal of Ovarian Research. 13, 9 p., 59.

Satisfaction with care and adherence to treatment when using patient reported outcomes to individualize follow-up care for women with early breast cancer - a pilot randomized controlled trial

Riis, C. L., Jensen, P. T., Bechmann, T., Möller, S., Coulter, A. & Steffensen, K. D., Apr 2020, In: Acta oncologica (Stockholm, Sweden). 59, 4, p. 444-452

Proposing a Bill of Rights for Patients With Cancer

Jacobson, J. O., Berry, L. L., Spears, P. A., Steffensen, K. D. & Attai, D. J., 1. Mar 2020, In: Journal of Oncology Practice. 16, 3, p. 121-123

Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer

Abildgaard, C., Canto, L. M. D., Dahl Steffensen, K. & Rogatto, S. R., 20. Jan 2020, In: Frontiers in Oncology. 9, 17 p., 1549.

Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer

Rusan, M., Andersen, R. F., Jakobsen, A. & Steffensen, K. D., Jan 2020, In: European journal of cancer (Oxford, England : 1990). 125, p. 121-129

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., Cloven, N. G., Oaknin, A., DiSilvestro, P. A., Morgan, M. A., Nam, J-H., Leath, C. A., Nicum, S., Hagemann, A. R., Littell, R. D., Cella, D. & 12 others, Baron-Hay, S., Garcia-Donas, J., Mizuno, M., Bell-McGuinn, K., Sullivan, D. M., Bach, B. A., Bhattacharya, S., Ratajczak, C. K., Ansell, P. J., Dinh, M. H., Aghajanian, C. & Bookman, M. A., 19. Dec 2019, In: The New England Journal of Medicine. 381, 25, p. 2403-2415

The impact of a patient decision aid on shared decision-making behaviour in oncology care and pulmonary medicine: A field study based on real-life observations

Olling, K., Stie, M., Winther, B. & Dahl Steffensen, K., Dec 2019, In: Journal of Evaluation in Clinical Practice. 25, 6, p. 1121-1130

A prospective cohort study of shared decision making in lung cancer diagnostics: Impact of using a patient decision aid

Søndergaard, S. R., Madsen, P. H., Hilberg, O., Jensen, K. M., Olling, K. & Steffensen, K. D., Nov 2019, In: Patient Education and Counseling. 102, 11, p. 1961-1968

Shared decision making when patients consider surgery for lumbar herniated disc: development and test of a patient decision aid

Andersen, S. B., Andersen, M. Ø., Carreon, L. Y., Coulter, A. & Steffensen, K. D., 4. Oct 2019, In: BMC Medical Informatics and Decision Making. 19, 9 p., 190.

Proactive use of PROMs in ovarian cancer survivors: a systematic review

Kargo, A. S., Coulter, A., Jensen, P. T. & Steffensen, K. D., 15. Jul 2019, In: Journal of Ovarian Research. 12, 8 p., 63.

Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer

Hansen, T. F., Nederby, L., Zedan, A. H., Mejlholm, I., Henriksen, J. R., Dahl Steffensen, K., Thomsen, C. B., Raunkilde, L., Jensen, L. H. & Jakobsen, A., Jul 2019, In: Translational Oncology. 12, 7, p. 968-972

Development of a patient decision aid template for use in different clinical settings

Olling, K., Bechmann, T., Madsen, P. H., Hugger Jakobsen, E., Toftdahl, D. B., Hilberg, O., Coulter, A. & Dahl Steffensen, K., Jun 2019, In: European Journal for Person Centered Healthcare . 7, 1

What matters in clinical trial decision-making: a systematic review of interviews exploring cancer patients' experiences

Gregersen, T. A., Birkelund, R., Wolderslund, M., Netsey-Afedo, M. L., Steffensen, K. D. & Ammentorp, J., Jun 2019, In: Scandinavian Journal of Caring Sciences. 33, 2, p. 266-278

Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy

Halaska, M. J., Uzan, C., Han, S. N., Fruscio, R., Dahl Steffensen, K., Van Calster, B., Stankusova, H., Delle Marchette, M., Mephon, A., Rouzier, R., Witteveen, P. O., Vergani, P., Van Calsteren, K., Rob, L. & Amant, F., 7. May 2019, In: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 29, 4, p. 676-682

Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review

Riis, C. L., Bechmann, T., Jensen, P. T., Coulter, A. & Steffensen, K. D., 27. Mar 2019, In: Patient Related Outcome Measures. 10, p. 117-127

Delta tocotrienol in recurrent ovarian cancer. A phase II trial

Thomsen, C. B., Andersen, R. F., Steffensen, K. D., Adimi, P. & Jakobsen, A., Mar 2019, In: Pharmacological Research. 141, p. 392-396

Factors Affecting Patient Decision-making on Surgery for Lumbar Disc Herniation

Andersen, S. B., Birkelund, R., Andersen, M. Ø., Carreon, L. Y., Coulter, A. & Steffensen, K. D., 15. Jan 2019, In: Spine. 44, 2, p. 143-149

The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer

Hjortkjær, M., Malik Aagaard Jørgensen, M., Waldstrøm, M., Ørnskov, D., Søgaard-Andersen, E., Jakobsen, A. & Dahl Steffensen, K., Jan 2019, In: International Journal of Gynecological Cancer. 29, 1, p. 166-173

A design-led patient campaign development process for disseminating the concept of shared decision making

Akoglu, C., Dankl, K. & Dahl Steffensen, K., 2019, In: Design for Health. 3, 2, p. 305-323

Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy

Boucek, J., de Haan, J., Halaska, M. J., Plzak, J., Van Calsteren, K., de Groot, C. J. M., Dahl Steffensen, K., Fruscio, R., Massolt, E. T., Klaritsch, P., Zola, P., Amant, F. & International Network on Cancer, Infertility, and Pregnancy, Jun 2018, In: The Laryngoscope. 128, 6, p. 1493-1500

Behandling af primær og recidiverende ovariecancer

Rosendahl, M., Mosgaard, B. J. & Steffensen, K. D., 22. Jan 2018, In: Ugeskrift for Laeger. 180, 4, p. 2-6 V03170213.

Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status

Hjortkjær, M., Kanstrup, H., Jakobsen, A. & Dahl Steffensen, K., 1. Jan 2018, In: Cancer Treatment and Research Communications. 14, p. 7-12

Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy

International Network on Cancer, Infertility and Pregnancy, 2018, In: Breast Cancer Research and Treatment. 168, 2, p. 551-557

Experiences of involvement in decision-making for patients with breast cancer: A phenomenological-hermeneutical study

Christoffersen, N., Olling, K., Dahl Steffensen, K. & Birkelund, R., 2018, In: European Journal for Person Centered Healthcare . 6, 2, p. 237-247

How participatory action research changed our view of the challenges of shared decision-making training

Ammentorp, J., Wolderslund, M., Timmermann, C., Larsen, H., Dahl Steffensen, K., Nielsen, A., Lau, M., Winther, B., Jensen, L. H., Assing Hvidt, E., Hvidt, N. C. & Gulbrandsen, P., 2018, In: Patient Education and Counseling. 101, 4, p. 639-646

Lessons in Integrating Shared Decision-Making Into Cancer Care

Steffensen, K. D., Vinter, M., Crüger, D., Dankl, K., Coulter, A., Stuart, B. & Berry, L. L., 2018, In: Journal of Oncology Practice. 14, 4, p. 229-235

Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients

de Haan, J., Verheecke, M., Van Calsteren, K., Van Calster, B., Shmakov, R. G., Mhallem Gziri, M., Halaska, M. J., Fruscio, R., Lok, C. A. R., Boere, I. A., Zola, P., Ottevanger, P. B., de Groot, C. J. M., Peccatori, F. A., Dahl Steffensen, K., Cardonick, E. H., Polushkina, E., Rob, L., Ceppi, L., Sukhikh, G. T. & 3 others, Han, S. N., Amant, F. & International Network on Cancer and Infertility Pregnancy (INCIP), 2018, In: Lancet Oncology. 19, 3, p. 337-346

Clopidogrel paclitaxel drug-drug interaction: A pharmacoepidemiologic study

Agergaard, K., Mau-Sørensen, M., Stage, T. B., Jørgensen, T. L., Hassel, R. E., Dahl Steffensen, K., Pedersen, J. W., Milo, M. L. H., Poulsen, S. H., Pottegård, A., Hallas, J., Brøsen, K. & Bergmann, T. K., Sep 2017, In: Clinical Pharmacology and Therapeutics. 102, 3, p. 547-553

Implementing shared decision making in Denmark: First steps and future focus areas

Dahl Steffensen, K., Hjelholt Baker, V. & Vinter, M. M., Jun 2017, In: Zeitschrift fuer Evidenz, Fortbildung und Qualitaet im Gesundheitswesen. 123-124, p. 36-40

Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma

de Haan, J., Lok, C. A., de Groot, C. J. M., Crijns, M. B., Van Calsteren, K., Dahl Steffensen, K., Halaska, M. J., Altintas, S., Boere, I. A., Fruscio, R., Kolawa, W., Witteveen, P. O., Amant, F. & International Network on Cancer, Infertility and Pregnancy (INCIP), Jun 2017, In: Melanoma Research. 27, 3, p. 218-223

Ovariecancer: tidlig opsporing i almen praksis og behandling

Jensen, P. T. & Dahl Steffensen, K., 2017, In: Best Practice - Almen praksis.

The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection

Hjortkjær, M., Waldstrøm, M., Jakobsen, A., Kanstrup, H., Søgaard-Andersen, E. & Dahl Steffensen, K., 2017, In: International Journal of Gynecological Pathology. 36, 2, p. 180-189

Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study

Steffensen, K. D., Adimi, P. & Jakobsen, A., 2017, In: International Journal of Gynecological Cancer. 27, 9, p. 1842-1849

The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab

Boisen, M. K., Madsen, C. V., Dehlendorff, C., Jakobsen, A., Johansen, J. S. & Dahl Steffensen, K., Oct 2016, In: International Journal of Gynecological Cancer. 26, 8, p. 1390-1398

Post-mortem testing; germline *BRCA1/2* variant detection using archival FFPE non-tumor tissue: A new paradigm in genetic counseling

Petersen, A. H., Jørgensen, M. M. A., Nielsen, H. R., Dahl Steffensen, K., Waldstrøm, M. & Bojesen, A., Aug 2016, In: European Journal of Human Genetics. 24, 8, p. 1104-1111

A case report of long term bevacizumab treatment in multiresistant ovarian cancer

Kargo, A. S., Adimi, P. & Dahl-Steffensen, K., 19. Jun 2016, In: International Journal of Cancer Therapy and Oncology. 4, 2, 4 p., 4214.

Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I., Lund, B., Sørensen, S. M., Petzold, M. & Jakobsen, A., 2016, In: Oncology Letters. 11, 6, p. 3967-3974

Cancer under graviditeten

Pedersen, B. W., Storgaard, L., Clausen, M. B., Kroman, N., Langhoff-Roos, J. & Steffensen, K. D., 29. Jun 2015, In: Ugeskrift for Laeger. 177, 27, 5 p., V12140714.

Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab

Steffensen, K. D., Madsen, C. V., Andersen, R. F., Waldstrøm, M., Adimi, P. & Jakobsen, A., Oct 2014, In: European Journal of Cancer. 50, 15, p. 2611-2618 8 p.

Primary brain tumours, meningiomas and brain metastases in pregnancy: report on 27 cases and review of literature

Verheecke, M., Halaska, M. J., Lok, C. A., Ottevanger, P. B., Fruscio, R., Dahl Steffensen, K., Kolawa, W., Gziri, M. M., Han, S. N., Van Calsteren, K., Van den Heuvel, F., De Vleeschouwer, S., Clement, P. M., Menten, J., Amant, F. & ESGO 'Cancer in Pregnancy' Task Force, May 2014, In: European Journal of Cancer. 50, 8, p. 1462-1471 10 p.

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression

Steffensen, K. D., Smoter, M., Waldstrøm, M., Grala, B., Bodnar, L., Stec, R., Szczylik, C. & Jakobsen, A., May 2014, In: International Journal of Oncology. 44, 5, p. 1736-1744 9 p.

Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting

Amant, F., Halaska, M. J., Fumagalli, M., Dahl Steffensen, K., Lok, C., Van Calsteren, K., Han, S. N., Mir, O., Fruscio, R., Uzan, C., Maxwell, C., Dekrem, J., Strauven, G., Mhallem Gziri, M., Kesic, V., Berveiller, P., van den Heuvel, F., Ottevanger, P. B., Vergote, I., Lishner, M. & 3 others, Morice, P., Nulman, I. & ESGO 'Cancer in Pregnancy' Task Force, Mar 2014, In: International Journal of Gynecological Cancer. 24, 3, p. 394-403

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)

You, B., Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Varsellona, N., Emons, G., Rehman, K., Steffensen, K. D., Reinhaller, A., Pujade-Lauraine, E. & Oza, A., Aug 2013, In: Gynecologic Oncology. 130, 2, p. 289-294

The need for more workshops in laparoscopic surgery and surgical anatomy for European gynaecological oncology trainees: a survey by the European Network of Young Gynaecological Oncologists

Manchanda, R., Halaska, M. J., Piek, J. M., Grabowski, J. P., Haidopoulos, D., Zapardiel, I., Gultekin, M., Vranes, B., Dallaku, K., Bossart, M., European Network of Young Gynecological Oncologists (ENYGO) & Dahl Steffensen, K., Jul 2013, In: International Journal of Gynecological Cancer. 23, 6, p. 1127-1132

Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer

Bechmann, T., Andersen, R. F., Pallisgaard, N., Madsen, J. S., Maae, E., Jakobsen, E. H., Bak Jylling, A. M., Steffensen, K. D. & Jakobsen, A., Jun 2013, In: Journal of Cancer Research and Clinical Oncology. Supplement. 139, 6, p. 995-1003 9 p.

Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy

Bechmann, T., Olsen, D. A., Jakobsen, E. H., Madsen, J. S., Brandslund, I., Jylling, A. M. B., Steffensen, K. D. & Jakobsen, A., Apr 2013, In: Current Oncology Reports (Online). 29, 4, p. 1475-1482 8 p.

Cancer in pregnancy: a survey of current clinical practice

Han, S. N., Kesic, V. I., Van Calsteren, K., Petkovic, S., Amant, F., ESGO 'Cancer in Pregnancy' Task Force & Dahl Steffensen, K., 2013, In: European Journal of Obstetrics & Gynecology and Reproductive Biology. 167, 1, p. 18-23

Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study

Steffensen, K. D., Waldstrøm, M., Pallisgård, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 2013, In: International Journal of Gynecological Cancer. 23, 1, p. 73-80

Predicting brain metastases of breast cancer based on serum S100B and serum HER2

Bechmann, T., Madsen, J. S., Brandslund, I., Lund, E. D., Ormstrup, T., Jakobsen, E. H., Jylling, A. M. B., Steffensen, K. D. & Jakobsen, A., 2013, In: Oncology Letters. 6, 5, p. 1265-1270

Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up

Madsen, C. V., Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2012, In: Pathology Research International. 2012, p. 851432 8 p.

Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer

Madsen, C. V., Dahl Steffensen, K., Waldstrøm, M., Fredslund Andersen, R., Søgaaard, C., Brandslund, I. & Jakobsen, A., 2012, In: Clinical Ovarian and Other Gynecologic Cancer. 5, 1, p. 10-16

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer

Maae, E., Olsen, D. A., Steffensen, K. D., Jakobsen, E. H., Brandslund, I., Sørensen, F. B. & Jakobsen, A., 2012, In: Breast Cancer Research and Treatment. 133, 1, p. 257-265

Prognostic Impact of VEGFA Germline Polymorphisms in Patients with HER2-positive Primary Breast Cancer

Maae, E., Fredslund Andersen, R., Dahl Steffensen, K., Jakobsen, E. H., Brandslund, I., Sørensen, F. B. & Jakobsen, A., 2012, In: Anticancer Research. 32, 9, p. 3619-3627

Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab

Madsen, C. V., Steffensen, K. D., Olsen, D. A., Waldstrøm, M., Smerdel, M., Adimi, P., Brandslund, I. & Jakobsen, A., 2012, In: Journal of Ovarian Research. 5, 1, p. 23

Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors

Madsen, C. V., Steffensen, K. D., Olsen, D. A., Waldstrøm, M., Søgaaard, C., Brandslund, I. & Jakobsen, A., 2012, In: Anticancer Research. 32, 9, p. 3817-3825

The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients

Steffensen, K. D., Waldstrøm, M., Brandslund, I., Petzold, M. & Jakobsen, A., 2012, In: International Journal of Gynecological Cancer. 22, 9, p. 1474-1482

Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast

Maae, E., Nielsen, M., Dahl Steffensen, K., Jakobsen, E. H., Jakobsen, A. & Sørensen, F. B., Aug 2011, In: Journal of Histochemistry and Cytochemistry. 59, 8, p. 750-760

DNA-Repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival
Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2011, In: Journal of Cancer Therapy. 2, p. 140-147 7 p.

Gynecologic oncology training systems in europe: a report from the European network of young gynaecological oncologists

Gultekin, M., Dursun, P., Vranes, B., Laky, R., Bossart, M., Grabowski, J. P., Piek, J. M. J., Manchanda, R., Grimm, C., Dallaku, K., Babloyan, S., Moisei, A., Van Gorp, T., Cadron, I., Markov, P., Micevska, A., Halaska, M., Steffensen, K. D., Gristsenko, L., Nissi, R. & 20 others, Lambaudie, E., Tsitsishvili, Z., Haidopoulos, D., Tsolakidis, D., Novak, Z., Peiretti, M., Dunenova, G., Macuks, R., Hetland, T. E., Michelsen, T. M., Martins, F. C., Achimas-Cadariu, P., Ulrikh, E. A., Uharcek, P., Malic, S., Ognjenovic, D., Zapardiel, I., Johann, S., Sukhin, V. S. & Manchanda, R., 2011, In: International Journal of Gynecological Cancer. 21, 8, p. 1500-6 7 p.

Improved classification of epithelial ovarian cancer: results of 3 danish cohorts

Steffensen, K. D., Waldstrøm, M., Grove, A., Lund, B., Pallisgård, N. & Jakobsen, A., 2011, In: International Journal of Gynecological Cancer. 21, 9, p. 1592-600 9 p.

Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer

Steffensen, K. D., Alvero, A. B., Yang, Y., Waldstrøm, M., Hui, P., Holmberg, J. C., Silasi, D-A., Jakobsen, A., Rutherford, T. & Mor, G., 2011, In: Journal of Oncology. 2011, p. 620523 12 p.

Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients

Steffensen, K. D., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 2011, In: International Journal of Gynecological Cancer. 21, 6, p. 1040-7 8 p.

The prognostic importance of EGFR and COX-2 expression in cervix cancer stages IIb-IVa

Adimi, P., Dahl Steffensen, K., Schledermann, D., Rasmussen, E. R. & Jakobsen, A., 2011, In: Journal of Cancer Therapy. 2, 1, p. 9-15

The prognostic value of Syndecan-1 in ovarian cancer patients with long-term follow-up

Madsen, C. V., Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2011, In: Clinical Ovarian Cancer and Other Gynecologic Malignancies. 4, 1, p. 12-18

VEGF in the development of ovarian malignancy

Smerdel, M., Dahl Steffensen, K., Waldstrøm, M., Fredslund Andersen, R., Olsen, D. A., Brandslund, I. & Jakobsen, A., 2011, In: Clinical Ovarian Cancer and Other Gynecologic Malignancies. 4, 1, p. 19-25

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab

Smerdel, M. P., Steffensen, K. D., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 1. Aug 2010, In: Gynecologic Oncology. 118, 2, p. 167-71 5 p.

Supraclavicular recurrence after early breast cancer: a curable condition?

Pedersen, A. N., Møller, S., Steffensen, K. D., Haahr, V., Jensen, M., Kempel, M. M., Jepsen, S. L., Madsen, E. L., Roslind, A., Sandberg, E., Schöllkopf, C., Sørensen, P. G., Windfeldt, K. M. & Andersson, M., 8. May 2010, In: Breast Cancer Research and Treatment. 125, 7, p. 815-822

The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer

Steffensen, K. D., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 5. Jan 2010, In: Gynecologic Oncology. 117, 1, p. 109-116

Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer

Steffensen, K. D., Waldstrøm, M., Christensen, R. K., Bartels, A., Brünner, N. & Jakobsen, A., 1. Jan 2010, In: BMC Cancer. 10, p. 185

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer

Steffensen, K. D., Waldstrøm, M. & Jakobsen, A., 1. Jul 2009, In: International Journal of Gynecological Cancer. 19, 5, p. 820-5 5 p.

Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer

Smerdel, M., Waldstrøm, M., Brandslund, I., Steffensen, K. D., Andersen, R. F. & Jakobsen, A., 1. May 2009, In: International Journal of Gynecological Cancer. 19, 4, p. 578-84 6 p.

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

Alvero, A. B., Chen, R., Fu, H-H., Montagna, M., Schwartz, P. E., Rutherford, T., Silasi, D-A., Steffensen, K. D., Waldstrøm, M., Visintin, I. & Mor, G., 1. Jan 2009, In: Cell Cycle. 8, 1, p. 158-66 8 p.

Preoperative serum levels of epidermal growth factor receptor, HER2, and vascular endothelial growth factor in malignant and benign ovarian tumors

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Knudsen, H. J., Brandslund, I. & Jakobsen, A., Dec 2008, In: Clinical Ovarian and Other Gynecologic Cancer. 1, 2, p. 127-134

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Dahl Steffensen, K., Waldstrøm, M., Fredslund Andersen, R., Olsen, D. A., Jeppesen, U., Knudsen, H. J., Brandslund, I. & Jakobsen, A., 1. Jul 2008, In: International Journal of Oncology. 33, 1, p. 195-204 9 p.

Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors

Steffensen, K. D., Waldstrøm, M., Olsen, D. A., Corydon, T., Lorentzen, K. A., Knudsen, H. J., Jeppesen, U., Brandslund, I. & Jakobsen, A., 1. Jun 2008, In: Clinical Cancer Research. 14, 11, p. 3278-3282 4 p.

Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells

Chen, R., Alvero, A. B., Silasi, D-A., Steffensen, K. D. & Mor, G., 7. Jan 2008, In: Oncogene. 27, 2, p. 225-233 8 p.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 24. Oct 2007, In: International Journal of Gynecological Cancer.

The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Jakobsen, E., Brandslund, I. & Jakobsen, A., 2007, In: International Journal of Gynecological Cancer. 17, 4, p. 798-807 9 p.

Publications - abstracts peer reviewed

Bevacizumab in heavily pre-treated ovarian cancer patients and the predictive value of serum VEGF

Smerdel, M., Dahl Steffensen, K., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 2009, *Abstracts*. European Cancer Organization (ECCO)

Publications - posters

National coverage of biological materials for translational research in the Danish cancerbiobank (RBGB) and of corresponding clinical data in the Danish Gynecological Cancer Database (DGCD): 645 - Poster Session

Høgdal, E., Schnack, T., Dahl Steffensen, K., Jochumsen, K., Kahr, H. S., Hjorth Ingerslev, K., Antonsen, S. L., Christensen, IJ. & Høgdall, C. K., Mar 2020.

Fællesbeslutningstagnung ved recidiv af højgradsgliom. Poster præsentation

Sørensen Von Essen, H., Piil, K., Dahl Steffensen, K. & Rom Poulsen, F., 21. Jan 2020.

A study in optimizing follow up for postmenopausal women with breast cancer treated with adjuvant endocrine therapy
Lundgaard Riis, C., Bechmann, T., Jensen, P. T., Coulter, A. & Dahl Steffensen, K., 29. Aug 2019.

Blood natural killer cells as a new, independent prognostic factor in recurrent ovarian cancer
Henriksen, J. R., Nederby, L., Donskov, F., Waldstrøm, M., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., 29. Aug 2019.

Fælles beslutningstagning for patienter med recidiv af højgradsgliom – hvordan gør vi og er det overhovedet relevant?
Sørensen Von Essen, H., Piil, K., Dahl Steffensen, K. & Rom Poulsen, F., 29. Aug 2019.

HOXA9 methylation as a prognostic marker in platinum-resistant ovarian cancer
Faaborg, L., Henriksen, J. R., Fredslund Andersen, R., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., 29. Aug 2019.

Tissue immune response in ovarian cancer
Henriksen, J. R., Donskov, F., Jakobsen, A., Waldstrøm, M., Hjortkjær, M. & Dahl Steffensen, K., 1. Jun 2019.

Development of a decision aid to support ovarian cancer patient decide on CA125 biomarker monitoring
Kargo, A. S., Coulter, A., Jensen, P. T. & Dahl Steffensen, K., 12. Apr 2019.

Prognostic Impact of NK-cells, T-cells and PD-L1 in Ovarian Cancer
Henriksen, J. R., Waldstrøm, M., Donskov, F., Jakobsen, A., Hjortkjær, M. & Dahl Steffensen, K., 22. Mar 2019.

Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? - A scoping review
Riis, C. L., Bechmann, T., Jensen, P. T., Coulter, A. & Dahl Steffensen, K., 2019.

CABAZITAXEL - A TREATMENT OPTION IN RECURRENT PLATINUM-RESISTANT OVARIAN CANCER
Madsen, C. V., Adimi, P., Jakobsen, A. & Dahl Steffensen, K., 16. Sep 2018.

SHARED DECISION MAKING IN THE CARE FOR THE GYNECOLOGIC CANCER PATIENT
Mette, H., Fokdal, L. U., Ør Knudsen, A., Madsen, C. V., Jensen, P. T., Lundvall, L., Olling, K., Lemley, B., Blou, D., Hanne, B. & Dahl Steffensen, K., 15. Sep 2018.

DEVELOPMENT OF A PATIENT DECISION AID TEMPLATE FOR USE IN DIFFERENT CLINICAL SETTINGS
Olling, K., Bechmann, T., Madsen, P. H., Hugger Jakobsen, E., Hilberg, O., Coulter, A. & Dahl Steffensen, K., 30. Aug 2018.

Kan anvendelse af Patient Reported Outcome Measures (PROM) forbedre opfølgningen af ovariecancer patienter? PROMova, et national projekt.
Kargo, A. S., Coulter, A., Hjøllund, N. H. I., Jensen, P. T. & Dahl Steffensen, K., 30. Aug 2018.

Shared decision making in decision on adjuvant radiotherapy for early stage breast cancer patients
Bechmann, T., Ellegaard, M-B. B., Hugger Jakobsen, E., Offersen, B. V., Bøje, C. R., Zachariae, B. & Dahl Steffensen, K., 30. Aug 2018.

Valg eller fravalg af CA125 blodprøver ved opfølgning af patienter med ovariecancer. Udvikling af et beslutningsstøtteværktøj
Kargo, A. S., Coulter, A., Jensen, P. T. & Dahl Steffensen, K., 30. Aug 2018.

Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.
Dahl Steffensen, K., Fredslund Andersen, R. & Jakobsen, A., 4. Jun 2018.

Optimeret opfølgning for brystkræftpatienter i sygehusregi

Riis, C. L., Bechmann, T., Jensen, P. T., Coulter, A. & Dahl Steffensen, K., 18. Jan 2018.

Factors affecting patient decision-making on surgery for lumbar herniated disc

Brogård Andersen, S., Birkelund, R., Andersen, M. Ø., Coulter, A., Carreon, L. Y. & Dahl Steffensen, K., 2018.

Individual survivorship program for ovarian cancer patients based on PROM and shared decision making - PROMova

Kargo, A. S., Coulter, A., Hjælland, N. H. I., Jensen, P. T. & Dahl Steffensen, K., 2018.

Validation and incorporation of oncologic and relapse data from Danish National Patient Registry (NPR) in the Danish Gynecological Cancer Database (DGCD)

Weng Ekman-Gade, A., Høgdall, C., Fagö-Olsen, C. L., Dahl Steffensen, K., Hjortkjær, M., Mejer Sørensen, S., Høgdall, E., Jochumsen, K., Antonsen, S. L., Ingerslev, K. H., Kahr, H. S. & Schnack Henriksen, T., 2018.

Is there a need for a Decision Aid in a Danish Spine Surgery Clinic or is Shared Decision Making already done?

Brogård Andersen, S., Andersen, M. Ø., Coulter, A., Carreon, L. Y. & Dahl Steffensen, K., 5. Jul 2017. 1 p.

Individuel survivorship program for ovarian cancer patients based on PROM and shared decision making - PROMova

Kargo, A. S., Coulter, A., Hjælland, N. H. I., Jensen, P. T. & Dahl Steffensen, K., 2017.

Neutrophils as a prognostic factor in the systemic treatment of Ovarian Cancer

Henriksen, J. R. & Dahl Steffensen, K., 29. Oct 2016.

LBA50 - Influence of concomitant clopidogrel consumption on development of paclitaxel-associated toxicity: A pharmacoepidemiological study

K, A., Mau-Sørensen, M., Stage, T. B., Dahl Steffensen, K., Hallas, J., Brøsen, K. & Bergmann, T. K., 8. Oct 2016.

A first step in shared decision making – developing a decision aid for the choice of anal cancer radiotherapy.

Olling, K., Wee, L., Jensen, L. H. & Dahl Steffensen, K., 19. Sep 2016.

A first step in shared decision making. Developing a decision aid for the choice of anal cancer radiotherapy

Olling, K., Wee, L., Jensen, L. H. & Dahl Steffensen, K., 19. Sep 2016.

Veliparib monotherapy to patients with BRCA germline mutation and platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer: A phase I/II study

Dahl Steffensen, K., Adimi, P. & Møller Jakobsen, A. K., 6. Jun 2016.

Forsøgs- eller standard behandling?

Gregersen, T. A., Ammentorp, J., Birkelund, R., Dahl Steffensen, K. & Wolderslund, M., 2016.

Prognosis of Patients with cervical cancer diagnosed during pregnancy

Halaska, M. J., Uzan, C., Han, S. N., Fruscio, R., Dahl Steffensen, K., Skultety, J., Giuliani, D., Mephon, A., Rouzier, R., Witteveen, P. O., Locatelli, A., Rob, L. & Amant, F., 2014.

The prognostic value of BRCA1 and PARP expression in epithelial ovarian carcinoma – immunohistochemical detection

Hjortkjær, M., Waldstrøm, M., Kanstrup, H., Søgaard-Andersen, E., Jakobsen, A. & Dahl Steffensen, K., 2014.

The clinical outcome in breast cancer patients with HER2 status determined by a quantitative ELISA technique

Bechmann, T., Jakobsen, E. H., Madsen, J. S., Brandslund, I., Olsen, D. A., Jylling, A. M. B., Dahl Steffensen, K. & Jakobsen, A., 5. May 2012.

Quantitative tissue HER2 protein concentration does not expand the group of patients eligible for adjuvant HER2-targeted therapy

Bechmann, T., Olsen, D. A., Jakobsen, E. H., Madsen, J. S., Brandslund, I., Jylling, A. M. B., Dahl Steffensen, K. & Jakobsen, A., 20. Apr 2012.

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer

Maae, E., Olsen, D. A., Dahl Steffensen, K., Jakobsen, E. H., Brandslund, I., Sørensen, F. B. & Jakobsen, A., Apr 2012.

Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast

Maae, E., Nielsen, M., Dahl Steffensen, K., Jakobsen, E. H., Jakobsen, A. & Sørensen, F. B., Mar 2012.

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study

Dahl Steffensen, K., Waldstrøm, M., Pallisgaard, N., Lund, B., Bergfeldt, K., Wihl, J., Kjeldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 2012.

The prognostic and predictive value of combined HE4 and CA125 in ovarian cancer patients

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I., Petzold, M. & Jakobsen, A., 2012.

The clinical significance of quantitative HER2 determination in breast cancer

Bechmann, T., Jakobsen, E. H., Madsen, J. S., Jylling, A. M. B., Dahl Steffensen, K. & Jakobsen, A., 10. Mar 2011.

Prognostic Impact of Prechemotherapy Human Epididymis Protein (HE4) and Cancer Antigen 125 (CA125) Levels in Ovarian Cancer Patients

Dahl Steffensen, K., Waldstrøm, M., Brandslund, I. & Jakobsen, A., 6. Mar 2011.

Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study.

You, B., Colombaro, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Fossati, R., Emons, G., Rehman, K. L., Petru, E., Gebbski, V., Burges, A., Tubiana-Matthieu, N., Hansen, M., Vasey, P. A., Denison, U., De Bruyne, P. & Oza, A. M., 2011.

Clinical aspects of vascular endothelial growth factor in breast cancer -Preliminary results of vascular endothelial growth factor single nucleotide polymorphisms analysis

Maae, E., Hugger Rasmussen, E., Dahl Steffensen, K., Sørensen, F. B., Brandslund, I. & Jakobsen, A., 2010.

Clinical aspects of vascular endothelial growth factor in breast cancer -Preliminary results of vascular endothelial growth factor single nucleotide polymorphisms analysis

Maae, E., Hugger Rasmussen, E., Dahl Steffensen, K., Sørensen, F. B., Brandslund, I. & Jakobsen, A., 2010.

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, non-randomized, multicenter, phase II trial

Dahl Steffensen, K., Waldstrøm, M., Lund, B., Bergfeldt, K., Kjeldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 2010.

Association of ERCC1 protein expression to platinum resistance in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M. & Jakobsen, A., 2009.

The predictive value of CD44, Myd88 and ERCC1 to the effect of chemotherapy in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Visintin, I., Silasi, D. & Jakobsen, A., 2009.

Absence of mutant epidermal growth factor receptor (EGFRVIII) in normal, benign, borderline and malignant ovarian tissue

Dahl Steffensen, K., Waldstrøm, M., Olsen, D. A., Corydon, T., Knudsen, H. J., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2008.

Multiplex serum tumor markers for the prediction of early relapse in ovarian cancer patients

Dahl Steffensen, K., Waldstrøm, M., Visintin, I., Brandslund, I. & Jakobsen, A., 2008.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2008.

Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors

Dahl Steffensen, K., Waldstrøm, M., Andersen, RF., Olsen, DA., Jeppesen, U., Knudsen, HJ., Brandslund, I. & Jakobsen, A., 2008.

The predictive value of CD44, Myd88 and ERCC1 to the effect of chemotherapy in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Visintin, I., Silasi, D., Jakobsen, A. & Mor, G., 2008.

The prognostic importance of EGFR and COX-2 expression in advanced cervix cancer

Adimi, P., Schledermann, D., Dahl Steffensen, K. & Jakobsen, A., 2008.

Comparison of immunohistochemistry and fluorescence in situ hybridization for the evaluation of Her-2 expression and prognostic value in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Jakobsen, E., Brandslund, I. & Jakobsen, A., 2007.

COX2 expression and relation to long term survival in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2007.

COX2 expression and relation to long-term survival in epithelial ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2007.

Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer

Dahl Steffensen, K., Waldstrøm, M., Jeppesen, U., Brandslund, I. & Jakobsen, A., 2007.

Academic background

PhD, PhD, University of Southern Denmark

2005 → 2008

Award Date: 18. Sep 2008

Cand Med, Aarhus University

Jan 1992 → Jan 1999

Award Date: 22. Jan 1999

Activities

Visiting scientist abroad